Completed PHASE3 INTERVENTIONAL 3-arm NCT02555150

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

A Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

Sponsor: Purdue Pharma LP

Conditions Attention Deficit Hyperactivity Disorder

Interventions PRC-063 Placebo lisdexamfetamine dimesylate

Updated 6 times since 2017 Last updated: Jan 17, 2017 Started: Sep 30, 2015 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02555150, this PHASE3 trial focuses on Attention Deficit Hyperactivity Disorder and remains completed. Sponsored by Purdue Pharma LP, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Purdue Pharma LP
Rhodes Pharmaceuticals, L.P.

Data source: Rhodes Pharmaceuticals, L.P.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States